Vivus hit a jackpot with Qnexa going so well. Normally, phase three is where a lot of problems come up in most drugs, however with so many agencies thinking that Vivus will start to rise, and with the...
Moneycentral.com tells me that this medical supply co. last year achieved a 3 year high in book value/share ($1.02) and also a 3 year LOW in debt/equity ratio (0.08). If that combination doesn't fit your...